The latest international news, analysis and features on the HIV epidemic from AVERT. Share your views and expertise with your peers in the comments box below the articles.
HIV is more proactively monitored among urban HIV patients than rural patients, and drug resistance and treatment failure is less prevalent. However outcomes for second line treatment remain similar.
Understanding the vaginal microbiome and how it impacts HIV risk could help develop more effective treatment and prevention strategies for young women in sub-Saharan Africa.
Treatment scale-up has had major public health benefits. But where resources are scarce, interventions to keep people in care could be more cost-effective than moving to treat everybody living with HIV after diagnosis.
With 17 million people now accessing antiretroviral treatment worldwide, HIV drug resistance has the potential to unravel progress towards the Fast-Track target of ending AIDS by 2030.
Adherence challenges with pre-exposure prophylaxis (PrEP) could be overcome if experimental long-acting HIV drug is found to be effective and acceptable.
A number of southern African countries are making good progress towards the 90-90-90 Fast-Track Targets, but efforts to reach younger populations need to be redoubled.
Near-universal uptake of HIV testing among men who were given self-tests by their partners in Kenya shows its feasibility as an intervention to reach hard-to-reach groups.
Injecting drug use accounted for 9% of all new HIV infections in the USA in 2014 – but new demographic trends among people who inject drugs present new challenges for the HIV response.
The world’s second largest antiretroviral treatment programme is now reaching just under half of all those living with HIV in India, but challenges remain to achieve UNAIDS’ 90-90-90 Fast-Track targets.
The UK has exceeded UNAIDS Fast-Track targets of getting people on treatment and virally suppressed, but falls behind on reaching those who are undiagnosed.